The Latest CBD Research: Q&A with Alice O’Leary-Randall
O’Leary-Randall dispels common CBD myths and outlines what current research suggests about the therapeutic properties of CBD, drug-to-drug interactions and best clinical practices for medical professionals.
February 6, 2020
The CBD industry’s explosive growth is quickly outpacing science, but with the passage of the 2018 Farm Bill, research has begun in earnest, and more is being known about the benefits of this now common cannabis compound and its uses.
Alice O’Leary-Randall has been on the forefront of the medical cannabis movement ever since her late husband, Robert C. Randall, became the first person in the U.S. to legally receive medical cannabis. Now the editor-in-chief of Mary’s Medicinals publications, O’Leary-Randall frequently writes and speaks on the issue. Here, she outlines some common CBD myths, as well as what current research suggests about the therapeutic properties of CBD, drug-to-drug interactions and best clinical practices for medical professionals.
Cannabis Business Times: What are some common CBD myths that have been dispelled through research?
Alice O’Leary-Randall: I think the most common one that I hear is that you can use CBD because that way you won’t fail the drug test at work. That’s a big one, and that is not true. There’s just enough THC in there that if you’re using it on a regular basis, like taking capsules every day or something like that, the THC can build up in the liver and thus into your bloodstream eventually and can skew a drug test.